| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/03/2001 | US6211371 Reacting an aryl isonirile with an isoquinolin-1-one compound |
| 04/03/2001 | US6211355 Reacting cobalamin compound with chelating compound to compound useful for in vivo imaging of organs and tumors |
| 04/03/2001 | US6211334 Cell-cycle regulatory proteins, and uses related thereto |
| 04/03/2001 | US6211244 Aromatic amines for complexing calcium |
| 04/03/2001 | US6211222 Substituted indazole derivatives and related compounds |
| 04/03/2001 | US6211210 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use |
| 04/03/2001 | US6211208 2-aminopyridines containing fused ring substituents |
| 04/03/2001 | US6211197 Carboxylic acid or tetrazole derivates; analgesics, antipyretics, and antiinflammatory agents; side effect reduction |
| 04/03/2001 | US6211193 Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives; antitumor and anticarcinogenic agents |
| 04/03/2001 | US6211192 Alkynyl-substituted camptothecins and process for their preparation |
| 04/03/2001 | US6211191 Integrin receptor antagonists |
| 04/03/2001 | US6211167 Arylsulfonanilide phosphates |
| 04/03/2001 | US6211166 Coadministered with a 5-fluorouracil derivative; anticarcinogenic agents |
| 04/03/2001 | US6211164 Sensitization of tumor cells |
| 04/03/2001 | US6211152 Formulations for peptide release |
| 04/03/2001 | US6210963 Autologous differentiated tissue aggregates; for the treatment of tumors; antitumor agents |
| 04/03/2001 | US6210946 Modified adenovirus containing a fiber replacement protein |
| 04/03/2001 | US6210917 By treating methylthioadenosine phosphorylase deficient cells with adenine synthesis inhibitor to deplete the target cells of adenosine 5'-triphosphate |
| 04/03/2001 | US6210913 Modulation of integrin-mediated signal transduction |
| 04/03/2001 | US6210890 Human peroxisomal thioesterase |
| 04/03/2001 | US6210708 Cationic virosomes as transfer system for genetic material |
| 04/03/2001 | US6210669 Methods and compositions for immunomodulation |
| 04/03/2001 | US6210668 Destruction of contaminating tumor cells in stem cell transplants using bispecific antibodies |
| 04/03/2001 | US6210664 Method for gene transfer to the central nervous system |
| 04/03/2001 | CA2149636C Method of activating photosensitive agents |
| 03/30/2001 | WO2003044525A1 Targeting cells having mad2 mutation for treatment and/or prevention of disease |
| 03/30/2001 | WO2003042411A2 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease |
| 03/30/2001 | WO2002090588A1 Interfering with telomere maintenance in treatment of diseases |
| 03/29/2001 | WO2001021831A1 Method for identifying novel genes involved in the regulation of angiogenesis, study of said genes and use thereof for therapeutic purposes |
| 03/29/2001 | WO2001021812A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | WO2001021799A1 Traf4 associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | WO2001021796A2 Gl50 molecules and uses therefor |
| 03/29/2001 | WO2001021771A2 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 03/29/2001 | WO2001021663A1 Pcna associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | WO2001021658A1 32 human secreted proteins |
| 03/29/2001 | WO2001021628A1 A substantially cell membrane impermeable compound and use thereof |
| 03/29/2001 | WO2001021620A2 Amine derivatives of benzo-4,5-thieno-2,3-d pyrimidines |
| 03/29/2001 | WO2001021619A1 N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent |
| 03/29/2001 | WO2001021602A1 Oxa- and thiazole derivatives useful as antidiabetic and antiobesity agents |
| 03/29/2001 | WO2001021598A1 Therapeutic quinazoline compounds |
| 03/29/2001 | WO2001021597A1 Therapeutic quinazoline derivatives |
| 03/29/2001 | WO2001021596A1 Quinazoline derivatives and their use as pharmaceuticals |
| 03/29/2001 | WO2001021595A1 Quinazoline derivatives |
| 03/29/2001 | WO2001021594A1 Quinazoline compounds and pharmaceutical compositions containing them |
| 03/29/2001 | WO2001021589A2 Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof |
| 03/29/2001 | WO2001021585A2 Bis(1-aziridino-1-hydroxyiminomethyl)-derivatives, method for the production thereof and use thereof as anti-tumoral agents |
| 03/29/2001 | WO2001021583A1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient |
| 03/29/2001 | WO2001021582A1 Biphenyl derivatives used as nhe-3 inhibitors |
| 03/29/2001 | WO2001021575A1 Anti-inflammatory nitro- and thia- fatty acids |
| 03/29/2001 | WO2001021216A1 Capsid-modified recombinant adenovirus and methods of use |
| 03/29/2001 | WO2001021207A2 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| 03/29/2001 | WO2001021204A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | WO2001021198A1 Method for reducing the risk of cancer |
| 03/29/2001 | WO2001021193A1 Hybrid peptides modulate the immune response |
| 03/29/2001 | WO2001021191A2 Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs |
| 03/29/2001 | WO2001021185A1 Novel pharmacological activities of curcuma longa extracts |
| 03/29/2001 | WO2001021174A1 Formulations of paclitaxel entrapped into nanoparticles of polymeric micelles |
| 03/29/2001 | WO2001021172A1 Anti-cancer nitro- and thia-fatty acids |
| 03/29/2001 | WO2001021152A1 Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
| 03/29/2001 | WO2001021137A1 Extracts of orange peel for prevention and treatment of cancer |
| 03/29/2001 | WO2001021135A2 Polymer conjugates of ara-c and ara-c derivatives |
| 03/29/2001 | WO2001002557A8 Neurotrophic factor receptor |
| 03/29/2001 | WO2000075139A3 Benzothiazinone and benzoxazinone compounds |
| 03/29/2001 | WO2000073294A3 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 03/29/2001 | WO2000066176A3 Agent for gene therapy and for the prevention of metastases, as well as for the gene therapy of tumors |
| 03/29/2001 | WO2000057188A3 Proteins associated with mammary cancer and method for detecting same |
| 03/29/2001 | WO2000047583A8 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 03/29/2001 | WO2000037487A8 αvβ6 INTEGRIN INHIBITORS |
| 03/29/2001 | WO2000032255A9 Polymeric coatings with controlled delivery of active agents |
| 03/29/2001 | WO2000012741A9 Inducible expression system |
| 03/29/2001 | US20010000075 Neurotactin and uses therefor |
| 03/29/2001 | DE19946289A1 Benzodiazepin-Derivate, deren Herstellung und Anwendung Benzodiazepine derivatives, their production and use |
| 03/29/2001 | DE19945982A1 Geschwindigkeitsbestimmte Partikel Certain particle velocity |
| 03/29/2001 | DE19945810A1 Substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Substituted benzimidazole derivatives, processes for their preparation and their use as medicaments |
| 03/29/2001 | DE19945302A1 Biphenylderivate als NHE-3-Inhibitoren Biphenyl as NHE-3 inhibitors |
| 03/29/2001 | DE19944767A1 N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel N-substituted 4-Aminopteridine, processes for their preparation and their use as medicaments |
| 03/29/2001 | CA2793128A1 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| 03/29/2001 | CA2387529A1 Biphenyl derivatives as nhe-3 inhibitors |
| 03/29/2001 | CA2387520A1 Amine derivatives |
| 03/29/2001 | CA2385879A1 Traf4 associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | CA2385697A1 Method for identifying novel genes involved in the regulation of angiogenesis, study of said genes and use thereof for therapeutic purposes |
| 03/29/2001 | CA2385552A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | CA2385480A1 32 human secreted proteins |
| 03/29/2001 | CA2385425A1 Pcna associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | CA2385257A1 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 03/29/2001 | CA2385105A1 Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof |
| 03/29/2001 | CA2384827A1 Capsid-modified recombinant adenovirus and methods of use |
| 03/29/2001 | CA2384816A1 Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs |
| 03/29/2001 | CA2384296A1 Therapeutic quinazoline derivatives |
| 03/29/2001 | CA2384291A1 Quinazoline derivatives and their use as pharmaceuticals |
| 03/29/2001 | CA2384284A1 Quinazoline derivatives |
| 03/29/2001 | CA2384282A1 Quinazoline compounds and pharmaceutical compositions containing them |
| 03/29/2001 | CA2383629A1 Hybrid peptides modulate the immune response |
| 03/29/2001 | CA2383598A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | CA2383574A1 Method for reducing the risk of cancer |
| 03/29/2001 | CA2383413A1 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| 03/29/2001 | CA2383240A1 Polymer conjugates of ara-c and ara-c derivatives |
| 03/29/2001 | CA2383110A1 Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant |
| 03/29/2001 | CA2351482A1 Novel pharmacological activities of curcuma longa extracts |
| 03/28/2001 | EP1087013A2 Immunoglobulins devoid of light chains |